{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:13:16Z","timestamp":1779347596364,"version":"3.51.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2026,5,14]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Hypoxia is a hallmark of aggressive breast cancers, particularly Triple-\nNegative Breast Cancer (TNBC), where stabilization of Hypoxia-Inducible Factor-1\u03b1 (HIF-1\u03b1)\nupregulates Carbonic Anhydrase IX (CAIX), thereby enabling tumor pH homeostasis, proliferation,\nand resistance to therapy. Selective CAIX inhibition, therefore, offers a promising therapeutic\nstrategy. In this study, a thiazolidine derivative was identified as a selective inhibitor of\nCAIX with the use of integrated computational, in vitro, and in vivo studies to develop targeted\ntherapy against TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A series of thiazolidinone derivatives was subjected to in silico molecular docking\nagainst human carbonic anhydrase isoforms. The most active compound, 2-(4-chlorophenyl)-3-\n(4-ethoxyphenyl)thiazolidin-4-one (BCS12), was tested and analyzed using 200 ns MD simulations\nto evaluate the stability of the complexes. Pharmacokinetic parameters were predicted\nusing ADME profiling. Cytotoxicity was evaluated in MDA-MB-231 and MDA-MB-468 breast\ncancer cells, with IC50 values of 15.49 \u03bcM and 18.81 \u03bcM, compared to 121.6 \u03bcM in noncancerous\nMCF-10A cells (n = 3, p &lt; 0.05). Free Radical generation, mitochondrial membrane\ndepolarization, and expression of apoptosis markers (Bax, Bcl-2, caspase 9, caspase 7, and\ncaspase 3, and PARP) were quantified using mechanistic studies in hypoxia-adapted MDA-MB-\n231 cells by RT-qPCR, western blotting, and immunofluorescence. The number of apoptotic\ncells was also determined by flow cytometry. The in vivo activity was assessed against DMBAinduced\nbreast tumor-bearing rats by histopathology and TUNEL staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>BCS12 showed strong docking affinity as well as stable binding with active-site residues\nof CAIX in simulations. It preferentially suppressed TNBC cell viability, promoted oxidative\nstress, impaired the integrity of mitochondria, and activated an intracellular apoptosis\npathway. In vivo, BCS12 treatment induces an increase of TUNEL-positive nuclei in a dosedependent\nmanner compared with the control, with significantly higher contrast index values at\n20 mg\/kg and 40 mg\/kg (p &lt; 0.0001). The apoptotic response was strongest in the 40 mg\/kg\ngroup, and was associated with a marked decrease in tumor burden and restoration of tissue architecture.\nThe lead compound reduced tumor mass, improved histological parameters, and increased\nTUNEL-positive apoptotic nuclei with an associated decrease in expression of CAIX\nand activation of pro-apoptotic proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Our findings suggest that BCS12 disrupts hypoxia-induced survival pathways\nthrough inhibition of CAIX to enhance TNBC cell sensitivity to apoptosis. These data reveal a\ntherapeutic benefit of selective CAIX inhibition to counteract hypoxia-induced therapy resistance\nand further insights into the mechanism underlying hypoxia-targeted therapies for aggressive\nbreast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BCS12 selectively inhibits CAIX, leading to the effective impairment of hypoxic\nadaptation and apoptosis in TNBC. The in silico, in vitro, and pre-clinical model data together\nprovide evidence for the candidacy of this compound as a lead candidate for hypoxia-targeted\ntherapy of breast cancer. Due to its unique chemical structure and therapeutic characteristics,\nBCS12 may be a candidate for patent filing for future translational development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115748928441521260224055625","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:43:32Z","timestamp":1779345812000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAIX\u2013HIF-1\u03b1 Inhibition by 2-(4-Chlorophenyl)-3-(4-Ethoxyphenyl) Thiazolidin-4-one (BCS12) Activates Caspase Cascade and PARP Cleavage,\nDriving Mitochondrial Apoptosis in Hypoxic Breast Cancer"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2460-2498","authenticated-orcid":true,"given":"Gaurav","family":"Ranjan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, 824236, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-2648","authenticated-orcid":true,"given":"Shakti Prasad","family":"Pattanayak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, 824236, India"},{"name":"Department of Biochemistry, School of Medicine, Case Western Reserve University, Woods Building, 2109 Adelbert  Road, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8066-9327","authenticated-orcid":true,"given":"Priyashree","family":"Sunita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Case Comprehensive Cancer Centre, Case Western Reserve University, Wolstein Research Building 2103 Cornell Rd, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928441521260224055625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/254048\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928441521260224055625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:43:52Z","timestamp":1779345832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/254048\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748928441521260224055625","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}